Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Reveals Details of New Withdrawal Rules for Off-Patent Branded Drugs
April 1, 2019
-
BUSINESS Daiichi Sankyo Bags US$6.9 Billion AstraZeneca Pact for Cancer Hopeful DS-8201, Announces CEO Change
April 1, 2019
-
INTERVIEW Kyokai Kenpo Director Yoshimori: Japan Should Eventually Use Cost-Effectiveness Assessment to Set Launch Prices
March 29, 2019
-
BUSINESS Sumitomo Dainippon Carves Out Pain Program, 2025 Launch Eyed for Rare Pediatric Disease
March 29, 2019
-
REGULATORY Opdivo Up for Yet Another Re-Pricing after CEA Confirmatory Analysis, but New Price Undisclosed
March 28, 2019
-
REGULATORY National Cancer Center’s Fujiwara Named New PMDA Chief
March 27, 2019
-
BUSINESS Kymriah OK’ed, Novartis Says It’s Not Up for Outcome-Based Pricing in Japan
March 27, 2019
-
BUSINESS Novartis Snags Japan Approval for CAR-T Therapy Kymriah
March 26, 2019
-
REGULATORY Nesp Biosame Likely to Be Priced at 70% of Originator as Stopgap Measure
March 26, 2019
-
INTERVIEW With HIV Back in Hand, Gilead Heading into Second Phase in Japan Market: Pres. Hermans
March 26, 2019
-
REGULATORY PMDA Chief Kondo to Step Down after 11 Years in Charge
March 25, 2019
-
REGULATORY LDP Lawmakers Not So Positive about Reflecting Societal Values to Drug Prices; They Don’t Know How
March 22, 2019
-
BUSINESS Biogen/Eisai’s Aducanumab Fails, Dashing Hopes in Alzheimer’s Field
March 22, 2019
-
BUSINESS Gilead Set to Duplicate Biktarvy Success in Japan with New Stand-Alone HIV Sales Force
March 20, 2019
-
BUSINESS Employee Sues Bayer Japan for Emotional Distress over Xarelto Scandal
March 19, 2019
-
ORGANIZATION Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established
March 18, 2019
-
BUSINESS Drug Makers, Wholesalers Establishing Supervisory Divisions as Detailing Guidelines Rollout Nears
March 15, 2019
-
REGULATORY MHLW to Promote Master Protocol Trials to Boost Efficiency in New Drug Development
March 14, 2019
-
BUSINESS Fujifilm Going Full Throttle in CDMO Biz with Buyout of Biogen Unit
March 13, 2019
-
REGULATORY Detailing Guidelines Casting Clouds over Drug Maker-Sponsored Press Seminars?
March 12, 2019
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…